Last reviewed · How we verify
NCT03285841
OCT-AF Imaging of Pre-cancers of Vulva and Cervix
trial testing OCT-AFI in Cervical Dysplasia in 20 participants. Terminated before completion.
30 June 2020
Quick facts
| Lead sponsor | British Columbia Cancer Agency |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 25 July 2019 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 December 2020 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- OCT-AFI
Conditions studied
- Cervical Dysplasia — all drugs for Cervical Dysplasia →
- Vulvar Dysplasia — all drugs for Vulvar Dysplasia →
- Precancerous Lesions — all drugs for Precancerous Lesions →
- Vulvar Cancer — all drugs for Vulvar Cancer →
Sponsor
British Columbia Cancer Agency
Who can join
18 and older, female only, with Cervical Dysplasia or Vulvar Dysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The multimodal imaging technology, OCT-AFI, will be used to image sites on the cervix, the endocervical canal and vulva. The imaging probe is small enough, it can be inserted into the endocervical canal for imaging. The probe can also be placed in a conformable holder that can be shaped to conform the the folds of the vulva for vulvar imaging. The resultant images will be compared to histology images. The objectives are to determine 1. feasibility of the technology in imaging vulva and its capability in detecting vulvar intraepithelial neoplasias 2. feasibility in imaging cervix from endocervical canal to transformation zone to ectocervix 3. if combined OCT with AFI increases the sensitivity of detecting high grade lesions in the cervix compared to just AFI alone (previous work was AFI alone).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03285841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cervical Dysplasia
Currently open trials in the same condition.
- NCT05640700 — Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia · recruiting
- NCT06452004 — Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC) · NA · active not recruiting
- NCT05606133 — Circulating Human Papilloma Virus (HPV) DNA for the Screening and Surveillance of Gynecologic Cancers · NA · recruiting
- NCT05774561 — Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring · recruiting
- NCT05051722 — Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer · recruiting
Other British Columbia Cancer Agency trials
Trials by the same sponsor.
- NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
- NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
- NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
- NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
- NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03285841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
- Last refreshed: 18 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03285841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing